Department Of Neurooncology
Investigator
Fabio Iwamoto, MD

fi2146@cumc.columbia.edu
Dr. Iwamoto is a neuro-oncologist whose previous training includes a neurology residency at NewYork-Presbyterian/Weill Cornell Medical Center and a neuro-oncology fellowship at Memorial Sloan-Kettering Cancer Center. For over three years, Dr. Iwamoto was an attending physician and an investigator at the Neuro-oncology Branch, a trans-institute branch of the National Cancer Institute and National Institute of Neurological Disorders and Stroke, in Bethesda, MD. At the intramural NIH, Dr. Iwamoto was a principal investigator in early phase clinical trials for brain tumors and worked with laboratory and computational scientists on several translational projects in brain tumors.
Dr. Iwamoto was recruited to Columbia University as the Deputy Director of the Neuro-oncology Division and is actively developing the clinical and translational research components of this program. He is an expert in the diagnosis, management, and treatment of brain and spinal cord tumors as well as neurological complications of cancer.
Condition |
Study Title |
Brain Tumors |
[ CLOSED ] A study for elderly individuals with malignant brain tumors using experimental drug, bevacizumab combined with temozolomide |
Brain Tumors |
[ CLOSED ] A study for adult patients with recurrent glioblastoma multiforme using study drug SL-701 |
Solid Tumors |
[ CLOSED ] A study for patients with advanced refractory solid tumors using study drug Varlilumab |
Brain Tumors |
[ CLOSED ] A study for patients with glioblastoma using study drug ICT-107 |
Brain Tumors |
[ CLOSED ] A study for patients with recurrent glioblastoma or anaplastic astrocytoma using study drug Toca 511 |
Brain Tumors |
[ CLOSED ] A study for patients with MGMT-Methylated Glioblastoma using study drug temozolomide |
Brain Tumors |
[ CLOSED ] A study for patients with glioblastoma using study drub nivolumab |
Lymphoma |
[ CLOSED ] A study for patients with Central Nervous System Lymphoma (PCNSL) or Primary Testicular Lymphoma (PTL) using study drug Nivolumab |
Brain Tumors |
[ CLOSED ] Study of Nivolumab (Study Drug) for Recurrent or Progressive IDH Mutant Gliomas |
Cancer |
[ CLOSED ] A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation |
Solid Tumors |
[ CLOSED ] Study of ASTX295 in Patients With Solid Tumors |
Brain Tumors |
[ CLOSED ] Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma |
Cancer |
[ CLOSED ] Study of ST101 in Patients with Advanced Solid Tumors |
Brain Tumors |
[ CLOSED ] Study of Tumor Treating Fields (Optune, 200kHz) with Radiation Therapy and Temozolomide for Treatment of Newly Diagnosed Glioblastoma |
Brain Cancer |
[ CLOSED ] Study of Tumor Treating Fields (Optune, 200kHz) with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma |
Brain Cancer |
Study of Chemotherapy Drug, Lomustine, in Addition to Temozolomide in Patients with Glioblastoma (GBM) |
Brain Tumors |
Study of Chemotherapy Drug, Lomustine, in Addition to Temozolomide in Patients with Glioblastoma (GBM) |
Brain Cancer |
[ CLOSED ] Study of Immune Therapy Drugs in Addition to the Usual Radiation Therapy for Patients with Brain Cancer (Glioblastoma) |
Brain Tumors |
[ CLOSED ] Study of Immune Therapy Drugs in Addition to the Usual Radiation Therapy for Patients with Brain Cancer (Glioblastoma) |
Lymphoma |
[ CLOSED ] Study of Pembrolizumab, Ibrutinib and Rituximab in Patients with Primary Central Nervous System Lymphoma (PCNSL) |
Brain Cancer |
Study of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma (PCNSL) |
Brain Tumors |
Study of Tirabrutinib in Patients with Primary Central Nervous System Lymphoma (PCNSL) |
Brain Cancer |
[ CLOSED ] Study of Safusidenib in Patients with Brain Glioma |
Brain Tumors |
[ CLOSED ] Study of Safusidenib in Patients with Brain Glioma |
Brain Tumors |
EF-41/KEYNOTE-D58: Study of Optune Concomitant with Temozolomide plus Pembrolizumab in Newly Diagnosed Glioblastoma |
Brain Tumors |
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Patients with Relapsed or Refractory PCNSL |